



## Intellia Therapeutics to Present at October Healthcare Investor Conferences

October 3, 2017

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:

### **Tuesday, October 10, 2017**

#### **Chardan Gene Therapy Conference**

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences & eXtellia

Location: New York, New York

Presentation Time: 2:45 pm EDT

### **Thursday, October 12, 2017**

#### **Jefferies Gene Therapy and Editing Summit**

Who: Nessian Bermingham, Ph.D., President, Chief Executive Officer and Founder

Location: New York, New York

Presentation Time: 1:40 pm EDT

A live webcast of Intellia's presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at [www.intelliatx.com](http://www.intelliatx.com). To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia's website for 14 days following each conference.

### **About Intellia Therapeutics**

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com); Follow us on Twitter @intelliatweets.

### **Intellia Contacts:**

#### **Media Contact:**

Jennifer Mound Smoter  
Senior Vice President, External Affairs  
& Communications  
+1 857-706-1071  
[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)

#### **Investor Contact:**

Lindsey Trickett  
Vice President, Investor Relations  
+1 857-285-6211  
[lindsey.trickett@intelliatx.com](mailto:lindsey.trickett@intelliatx.com)



Source: Intellia Therapeutics, Inc.